Indian Pharma Industry - PLI Scheme To Help India Become Aatmanirbhar In APIs: ICRA
BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
ICRA Research Report
The production linked incentive schemes announced by the Government of India for key raw materials such as bulk drugs and formulations with a total incentive outlay of Rs 210 billion will reduce import dependence and boost domestic production of high-value products and increase the value addition in exports.
High value-add pharmaceutical products are generally research and development intensive and difficult to manufacture products and include products such as complex generics, patented products, biologics among others.
Further, the government of India announced the promotion of bulk drug parks scheme with financial outlay of Rs 30 billion for three select states, which will provide infrastructure assistance to the active pharmaceutical ingredient players.
Click on the attachment to read the full report:
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.